A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.

PubWeight™: 1.86‹?› | Rank: Top 3%

🔗 View Article (PMID 12451189)

Published in Neurology on November 26, 2002

Authors

M Clanet1, E W Radue, L Kappos, H P Hartung, R Hohlfeld, M Sandberg-Wollheim, M F Kooijmans-Coutinho, E C Tsao, A W Sandrock, European IFNbeta-1a (Avonex) Dose-Comparison Study Investigators

Author Affiliations

1: Service de Neurologie, CHU Toulouse Purpan, Toulouse, France.

Articles citing this

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS. Neurology (2012) 1.76

Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol (2005) 1.50

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46

Needed in MS: evidence, not EVIDENCE. Neurology (2002) 1.36

When marketing and science intersect: do patients with MS benefit? Neurology (2002) 1.36

Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2004) 1.24

History of modern multiple sclerosis therapy. J Neurol (2005) 0.96

Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89

Escalating immunotherapy of multiple sclerosis--new aspects and practical application. J Neurol (2004) 0.88

Additive effects of combination treatment with anti-inflammatory and neuroprotective agents in experimental autoimmune encephalomyelitis. J Neuroimmunol (2009) 0.87

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis. Ther Adv Neurol Disord (2013) 0.87

Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol (2005) 0.85

The pros and cons of early treatment of relapsing forms of multiple sclerosis. J Neurol (2004) 0.83

The importance of maintaining effective therapy in multiple sclerosis. J Neurol (2005) 0.82

The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combination. Ther Adv Neurol Disord (2011) 0.82

Early stage and long term treatment of multiple sclerosis with interferon-beta. Biologics (2009) 0.81

Adverse events of interferon beta-1a: a prospective multi-centre international ICH-GCP-based CRO-supported external validation study in daily practice. PLoS One (2011) 0.79

Neutralizing antibodies against interferon-Beta. Ther Adv Neurol Disord (2008) 0.78

Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al. J Neurol (2011) 0.78

Development of interferon beta-neutralising antibodies in multiple sclerosis-a systematic review and meta-analysis. Eur J Clin Pharmacol (2015) 0.78

The role of glatiramer acetate in the early treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2010) 0.77

Relating relapse and T2 lesion changes to disability progression in multiple sclerosis: a systematic literature review and regression analysis. BMC Neurol (2013) 0.77

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis. The EVIDENCE study. J Neurol (2005) 0.76

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis. BMC Neurol (2014) 0.75

Incidence, characterization, and clinical impact analysis of peginterferon beta1a immunogenicity in patients with multiple sclerosis in the ADVANCE trial. Ther Adv Neurol Disord (2016) 0.75

Transplantation of Human Embryonic Stem Cells in Patients with Multiple Sclerosis and Lyme Disease. Am J Case Rep (2016) 0.75

[Recent advances in the pathogenesis and immunotherapy of multiple sclerosis]. Nervenarzt (2007) 0.75

Articles by these authors

Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med (2000) 4.50

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology (2006) 4.38

Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25

Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet (2009) 4.16

Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med (2000) 3.84

Histopathologic analysis of foci of signal loss on gradient-echo T2*-weighted MR images in patients with spontaneous intracerebral hemorrhage: evidence of microangiopathy-related microbleeds. AJNR Am J Neuroradiol (1999) 3.67

Differentiation between cellular apoptosis and necrosis by the combined use of in situ tailing and nick translation techniques. Lab Invest (1994) 3.58

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37

Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology (1996) 2.94

Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med (1999) 2.84

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. Eur J Neurol (2005) 2.67

Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology (2006) 2.64

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol (1998) 2.47

Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology (2002) 2.34

MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33

Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology (2008) 2.29

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26

Amplification and molecular cloning of HTLV-I sequences from DNA of multiple sclerosis patients. Science (1989) 2.23

The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17

FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07

The role of B cells and autoantibodies in multiple sclerosis. Ann Neurol (2000) 2.07

Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology (2011) 2.07

Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05

Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04

Multiple sclerosis and human T-cell lymphotropic retroviruses. Nature (1985) 1.96

Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93

Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93

[Current therapy of multiple sclerosis--high-dose intravenous therapy with corticosteroids]. Nervenarzt (1992) 1.93

P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol (2001) 1.92

The spectrum of immune responses to Campylobacter jejuni and glycoconjugates in Guillain-Barré syndrome and in other neuroimmunological disorders. Ann Neurol (1993) 1.92

MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90

A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler (2002) 1.86

Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet (1999) 1.81

MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology (1999) 1.80

Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78

Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78

NMO-IgG in the diagnosis of neuromyelitis optica. Neurology (2007) 1.77

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology (2011) 1.75

Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75

Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology (2001) 1.74

Bidirectional growth of the E. coli chromosome. Nat New Biol (1973) 1.73

Multiple sclerosis: side effects of interferon beta therapy and their management. Neurology (1999) 1.73

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73

The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72

Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology (2008) 1.72

Improved diffusion-weighted single-shot echo-planar imaging (EPI) in stroke using sensitivity encoding (SENSE). Magn Reson Med (2001) 1.69

Neuroimaging predictors of transition to psychosis--a systematic review and meta-analysis. Neurosci Biobehav Rev (2010) 1.65

The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65

TNFRSF1A R92Q mutation in association with a multiple sclerosis-like demyelinating syndrome. Neurology (2008) 1.63

Autoimmune human T lymphocytes specific for acetylcholine receptor. Nature (1984) 1.63

Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. Neurology (2002) 1.61

Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61

Isolation and characterization of an oligodendrocyte precursor-derived B-cell epitope in multiple sclerosis. Ann Neurol (1998) 1.60

Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59

Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57

MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56

Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55

Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54

Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A (2000) 1.53

MRI evidence of past cerebral microbleeds in a healthy elderly population. Neurology (1999) 1.50

Genetic control of multiple sclerosis: increased production of lymphotoxin and tumor necrosis factor-alpha by HLA-DR2+ T cells. Ann Neurol (1995) 1.50

Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today (2000) 1.49

The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49

Diffusion-weighted imaging of patients with subacute cerebral ischemia: comparison with conventional and contrast-enhanced MR imaging. AJNR Am J Neuroradiol (2000) 1.49

Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2008) 1.48

Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47

Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain (2000) 1.47

Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol (2008) 1.46

Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology (2003) 1.46

["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients]. Nervenarzt (2010) 1.45

[Pregnancy and immunomodulatory therapy in multiple sclerosis patients]. Nervenarzt (2006) 1.45

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45

The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol (2001) 1.43

Diversity of the anti-T-cell receptor immune response and its implications for T-cell vaccination therapy of multiple sclerosis. Brain (1998) 1.41

Towards a european network for multiple sclerosis trials (ENMST). Mult Scler (2003) 1.40

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol (2000) 1.39

Human myoblasts as antigen-presenting cells. J Immunol (1992) 1.39

[Physical trauma and multiple sclerosis]. Nervenarzt (1997) 1.38

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain (2000) 1.35

Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial. Arch Neurol (2001) 1.35

Substance P: binding properties and studies on cellular responses in guinea pig macrophages. J Immunol (1986) 1.34

Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology (2005) 1.33

Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain (2008) 1.33

Platelet activating factor (PAF) induces the oxidative burst in macrophages. Int J Immunopharmacol (1983) 1.31

The effects of antipsychotics on the brain: what have we learnt from structural imaging of schizophrenia?--a systematic review. Curr Pharm Des (2009) 1.31

Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS. Neurology (2011) 1.31

Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology (2001) 1.30

MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29

Molecular mechanisms of microglial activation. Adv Neuroimmunol (1996) 1.29